Johnson Matthey PLC (LON:JMAT – Get Free Report) insider Liam Condon acquired 21 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was acquired at an average price of GBX 1,598 ($21.11) per share, with a total value of £335.58 ($443.30).
Johnson Matthey Stock Up 1.5 %
Shares of JMAT opened at GBX 1,607 ($21.23) on Friday. The company has a debt-to-equity ratio of 63.15, a quick ratio of 0.76 and a current ratio of 1.45. Johnson Matthey PLC has a one year low of GBX 1,428.50 ($18.87) and a one year high of GBX 1,917.07 ($25.32). The stock has a market capitalization of £2.85 billion, a price-to-earnings ratio of 2,770.69, a PEG ratio of 49,242.50 and a beta of 0.95. The stock has a 50 day moving average price of GBX 1,617.40 and a 200 day moving average price of GBX 1,686.32.
Analyst Upgrades and Downgrades
JMAT has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 2,400 ($31.70) price objective on shares of Johnson Matthey in a research report on Monday, June 24th. Berenberg Bank restated a “hold” rating and issued a GBX 1,800 ($23.78) price objective on shares of Johnson Matthey in a research report on Tuesday, June 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,993.33 ($26.33).
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Read More
- Five stocks we like better than Johnson Matthey
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- With Risk Tolerance, One Size Does Not Fit All
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.